Skye Bioscience, Current Ratio vs. Return On Asset

SKYE Stock  USD 2.46  0.20  7.52%   
Based on the key profitability measurements obtained from Skye Bioscience,'s financial statements, Skye Bioscience, Common may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Skye Bioscience,'s ability to earn profits and add value for shareholders.
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
0.83812991
Current Value
0.8
Quarterly Volatility
3.02864125
 
Credit Downgrade
 
Yuan Drop
 
Covid
The current year's Sales General And Administrative To Revenue is expected to grow to 0.41, whereas Price To Sales Ratio is forecasted to decline to 274.83. At present, Skye Bioscience,'s Change To Netincome is projected to increase significantly based on the last few years of reporting. The current year's Income Quality is expected to grow to 0.39, whereas Income Tax Expense is forecasted to decline to 2,816.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.70.71
Fairly Down
Pretty Stable
For Skye Bioscience, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Skye Bioscience, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Skye Bioscience, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Skye Bioscience,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Skye Bioscience, Common over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.60)
Return On Assets
(0.30)
Return On Equity
(0.55)
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Skye Bioscience, Common Return On Asset vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Skye Bioscience,'s current stock value. Our valuation model uses many indicators to compare Skye Bioscience, value to that of its competitors to determine the firm's financial worth.
Skye Bioscience, Common is rated below average in current ratio category among its peers. It is rated below average in return on asset category among its peers . At present, Skye Bioscience,'s Current Ratio is projected to drop slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Skye Bioscience, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Skye Return On Asset vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Skye Bioscience,

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
0.91 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Skye Bioscience,

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.3
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Skye Return On Asset Comparison

Skye Bioscience, is currently under evaluation in return on asset category among its peers.

Skye Bioscience, Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Skye Bioscience,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Skye Bioscience, will eventually generate negative long term returns. The profitability progress is the general direction of Skye Bioscience,'s change in net profit over the period of time. It can combine multiple indicators of Skye Bioscience,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Loss-7.7 M-8.1 M
Income Tax Expense3.6 K2.8 K
Net Interest Income-806.3 K-846.6 K
Operating Income-13.7 M-14.4 M
Net Loss-37.6 M-35.8 M
Income Before Tax-37.6 M-35.8 M
Total Other Income Expense Net-24 M-22.8 M
Net Loss-37.6 M-35.8 M
Interest Income100 K105 K
Change To Netincome695.2 K983 K
Net Loss(5.37)(5.64)
Income Quality 0.37  0.39 
Net Income Per E B T 1.00  0.95 

Skye Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Skye Bioscience,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Skye Bioscience, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Skye Bioscience,'s important profitability drivers and their relationship over time.

Use Skye Bioscience, in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Skye Bioscience, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Skye Bioscience, will appreciate offsetting losses from the drop in the long position's value.

Skye Bioscience, Pair Trading

Skye Bioscience, Common Pair Trading Analysis

The ability to find closely correlated positions to Skye Bioscience, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Skye Bioscience, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Skye Bioscience, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Skye Bioscience, Common to buy it.
The correlation of Skye Bioscience, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Skye Bioscience, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Skye Bioscience, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Skye Bioscience, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Skye Bioscience, position

In addition to having Skye Bioscience, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Real Estate Thematic Idea Now

Real Estate
Real Estate Theme
Publicly traded companies that are involved in real estate development, property maintenance and management of real estate investment trusts (REIT) funds. The Real Estate theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:
Check out World Market Map.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
To fully project Skye Bioscience,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Skye Bioscience, Common at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Skye Bioscience,'s income statement, its balance sheet, and the statement of cash flows.
Potential Skye Bioscience, investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Skye Bioscience, investors may work on each financial statement separately, they are all related. The changes in Skye Bioscience,'s assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Skye Bioscience,'s income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.